TWD 79.5
(-3.52%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 55.53 Million TWD | 18.94% |
2022 | 46.69 Million TWD | -41.15% |
2021 | 79.34 Million TWD | -1.27% |
2020 | 80.36 Million TWD | -20.09% |
2019 | 100.56 Million TWD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q1 | 63.07 Million TWD | 13.57% |
2024 Q2 | 72.04 Million TWD | 14.22% |
2023 Q4 | 55.53 Million TWD | 7.75% |
2023 FY | 55.53 Million TWD | 18.94% |
2023 Q3 | 51.54 Million TWD | 5.19% |
2023 Q2 | 49 Million TWD | -2.53% |
2023 Q1 | 50.27 Million TWD | 7.66% |
2022 FY | 46.69 Million TWD | -41.15% |
2022 Q4 | 46.69 Million TWD | 0.0% |
2021 FY | 79.34 Million TWD | -1.27% |
2020 FY | 80.36 Million TWD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
DIVA Laboratories, Ltd. | 196.2 Million TWD | 71.694% |
Genetics Generation Advancement Corp. | 34.79 Million TWD | -59.601% |
Welgene Biotech Co.,Ltd. | 53.77 Million TWD | -3.288% |
Puriblood Medical Co., Ltd. | 24.24 Million TWD | -129.051% |
TFBS Bioscience Inc. | 8.84 Million TWD | -528.045% |